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Abstract
Background: Since establishment of Zimbabwe’s National Antiretroviral Therapy (ART) Programme in 2004, ART provision
has expanded from ,5,000 to 369,431 adults by 2011. However, patient outcomes are unexplored.
Objective: To determine improvement in health status, retention and factors associated with attrition among HIV-infected
patients on ART.
Methods: A retrospective review of abstracted patient records of adults$15 years who initiated ART from 2007 to 2009 was
done. Frequencies and medians were calculated for rates of retention in care and changes in key health status outcomes at
6, 12, 24 and 36 months respectively. Cox proportional hazards models were used to determine factors associated with
attrition.
Results: Of the 3,919 patients, 64% were female, 86% were either WHO clinical stage III or IV. Rates of patient retention at 6,
12, 24 and 36 months were 90.7%, 78.1%, 68.8% and 64.4%, respectively. After ART initiation, median weight gains at 6, 12,
and 24 months were 3, 4.5, and 5.0 kgs whilst median CD4+ cell count gains at 6, 12 and 24 months were 122, 157 and 279
cells/mL respectively. Factors associated with an increased risk of attrition included male gender (AHR 1.2; 95% CI, 1.1–1.4),
baseline WHO stage IV (AHR 1.7; 95% CI, 1.1–2.6), lower baseline body weight (AHR 2.0; 95% CI, 1.4–2. 8) and accessing care
from higher level healthcare facilities (AHR 3.5; 95% 1.1–11.2).
Conclusions: Our findings with regard to retention as well as clinical and immunological improvements following uptake of
ART, are similar to what has been found in other settings. Factors influencing attrition also mirror those found in other parts
of sub-Saharan Africa. These findings suggest the need to strengthen earlier diagnosis and treatment to further improve
treatment outcomes. Whilst decentralisation improves ART coverage it should be coupled with strategies aimed at
improving patient retention.
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Introduction
Globally, remarkable progress has been made in improving
access to ARVs whereby treatment coverage of 65% (9.7 million
people) [1] was achieved by end of 2012 compared to the 2015
target of 15 million agreed by United Nations Member States in
June 2011 [2]. Of all these HIV-infected people already on ART,
16% (1.6million people) were put on ART in 2012 alone [1]. In
Sub-Saharan Africa (SSA) which constitutes 69% of HIV
infections globally, access to ART increased from 50,000 to more
than 7.5 million between 2002 and 2012 [1].
Whilst there is need to scale up provision of this life-saving
treatment, there is need to monitor and ensure retention in care of
this growing cohort of patients so as to ensure ongoing receipt of
ART, evaluate the emergence of medication toxicities, and
identify the occurrence of treatment failure in order to switch
regimens [3]. The high attrition occurring among HIV-infected
patients in ART care in SSA has been widely documented, with a
meta-analysis of 39 cohorts from SSA showing that patient
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retention declined from 86% at 6 months to 77% by 36 months
after ART initiation. [4] In West Africa patient retention has been
reported at 76% by 1-year of follow-up whilst in Southern Africa
1-year retention ranges from 67–70% in Mozambique [5] to
82.7% in Botswana [6]
To further accelerate ART service coverage in SSA, there have
been recommendations to scale-up decentralisation of ART
services to primary health-care facilities coupled with task-shifting
of service provision to nurses [7]. This has resulted in increased
ART coverage in Malawi [8] and improved adherence and
retention [9,10,11].
Zimbabwe, with a population of 12,9 million is among countries
in the sub-Saharan region experiencing a mature HIV epidemic
with a decline in prevalence over the last decade from 27.2% in
1998 to 14.0 in 2012 whilst HIV incidence stabilised at 1.0% in
2012 [12]. The adult HIV prevalence observed in the 2010–2011
Zimbabwe Demographic and Health Survey showed slightly
higher HIV prevalence in urban areas than in rural areas and
ranged by province from 13% in Harare to 21% in Matebeleland
South [13]. The number of people living with HIV in 2012 was
estimated to be 1.3 million whilst the total estimated number of
people in need of antiretroviral therapy (ART) in 2012 was
621,673 adults and 108,263 children (based on a CD4,350 cells/
mm3) [12].
Zimbabwe suffered a socioeconomic crisis between 2001 and
2009 with extreme recession and hyperinflation which significantly
affected the national health system. During the crisis, there were
extreme shortages of health workers and essential medical supplies
[14]. The National Opportunistic Infections/Antiretroviral Ther-
apy (OI/ART) Programme in Zimbabwe was established in April
2004. Since 2008, both ART initiation and follow-up services have
been decentralised to lower level health facilities. In the period
under review in this study, there was a remarkable increase in
number of health facilities offering ART services and number of
patients receiving treatment; by January 2007 there were 101 sites
[15] providing treatment to 66,920 patients (11% coverage) [16]
which rose to 337 sites [17] offering ART to 218,589 patients
(49% coverage) [18] by December 2009 based on the WHO 2006
Guidelines.
The rapid expansion of ART programmes in settings with weak
health systems is associated with high mortality and loss of patients
to follow up [19,20]. With the on-going rapid expansion and
decentralization of ART in Zimbabwe; it was not clear how
treatment outcomes compared across levels of care. The purpose
of this study was therefore to i) describe baseline demographic and
clinical characteristics, and to determine ii) patient retention in
care iii) clinical outcomes and iv) factors associated with attrition
among HIV-infected patients enrolled in the National ART
Programme in Zimbabwe.
Methods
Study Design, Study Population and Sampling
A nationally representative multi-stage retrospective cohort
study was implemented using routine data from standard Ministry
of Health and Child Care (MOHCC) ART monitoring tools (e.g.,
facility patient medical records). Between October and December
2010, trained MOHCC personnel abstracted patient-level data
from facility medical records onto study questionnaires. Adult
patients $15 years old at ART initiation who initiated ART
between 2007 and 2009 at selected sites, and at least 12 months
prior to date of chart abstraction were eligible to be included in the
assessment (note: transfer-ins were excluded from the site-level
sampling frame).
To achieve a 95% confidence interval (CI) of +/22.5% around
the estimate for a conservative 12-month patient retention of 50%,
assuming a design effect of 2 and that 20% of medical records
were missing, it was determined that a sample size of $3,684
patients was needed. In order to simplify the sampling strategy, we
aimed to sample 4,000 charts of HIV-infected adults who initiated
ART at least 12 months prior to the date of chart abstraction.
During study planning, MOHCC reported data from May 2008
were used to define the clinic sample frame. By 31 May 2008,
103,806 adults had initiated ART at 104 public sector sites and 70
of the sites had $50 adult ART patients and hence they were
eligible for inclusion in the sampling frame. Sites were stratified by
site size (Small: 50–249 patients; Medium: 250–1000 patients;
Large: .1000 patients) and 40 facilities were selected via stratified
probability -proportional-to-size (PPS) sampling. Patient charts
were randomly selected at the 40 sites and the number of charts
selected was proportional to the size of the site. Patient charts
selected for data abstraction were searched for and retrieved by
clinic staff. Missing patient charts were replaced by the next
eligible patient record on the list of selected charts until the sample
size for the site had been reached.
Data from medical records were abstracted onto paper-based
questionnaires by trained data abstractors. For quality control
purposes, supervisors re-abstracted 10% of all abstracted medical
records. Data from the paper questionnaires were then hand
entered into an MS Access database and separately scanned into a
Teleform database after the data abstraction was completed. Data
from the two databases were compared using the COMPARWS
Macro [21] in SAS 9.2 (SAS Institute Inc., Cary, NC) to identify
discrepancies. Discrepancies were then resolved by referring back
to the paper questionnaires before the final dataset was cleaned
prior to data analysis.
Ethics review
This study was approved by the Medical Research Council of
Zimbabwe (MRCZ) and by the Institutional Review Board (IRB)
of the United States Centers for Disease Control and Prevention.
Both institutional review boards waived the need for written
informed consent from the participants since data in this study
were abstracted from existing medical records.
National ART Guidelines
During 2007–2009, adults were eligible for ART if they were
HIV positive and had a diagnosis of World Health Organization
(WHO) clinical stage IV, irrespective of CD4+ count; WHO
clinical stage III and a CD4+ cell count ,350 cells/mL; or WHO
clinical stage I or II and a CD4+ cell count ,200 cells/mL. Co-
trimoxazole preventive therapy (CPT) was indicated for all
symptomatic HIV-infected patients (clinical stages II, III and IV)
and/or if CD4+ cell count was ,200 cells/mL. Psychosocial
criteria for ART initiation, included completion of prescribed
counselling sessions and an assessment of adherence to CPT in the
past 3 months. Adherence to CPT was used to assess the likelihood
that the patient would adhere to ART.
According to national ART guidelines CPT adherence is
assessed by health workers through pill counts and self-reporting
by patients during each clinic visit and then recorded in the health
facility held card.
Recommended first-line ART regimens included Stavudine,
Lamivudine and Nevirapine. Single drug substitutions within the
same drug class were recommended for serious drug toxicities and
tuberculosis e.g. Zidovudine was used as an alternate 1st line for
Stavudine while Efavirenz was substituted for Nevirapine. After
initiating ART, a patient is seen every 2 weeks for the 1st month;
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thereafter monthly for another 3 months. This is important as
patients may present with inter-current illnesses, adverse drug
events, or immune reconstitution syndrome. If a patient is stable
after the initial 3 months; they are seen every 3 months thereafter.
It is government’s policy to provide ARV medicines free of charge
to patients. However, patients are expected to pay consultation
fees; laboratory-associated costs such as CD4 tests, Full Blood
Count and radiography (CXR) for ruling out chest pathologies.
Recommended clinical and laboratory monitoring indices
included patient weight, WHO clinical stage, development of
opportunistic infections, complete blood count (CBC), Alanine
Transaminase (ALT), serum creatinine, and where possible CD4+
cell counts. Routine clinical monitoring was to be conducted every
3 months; CBC and CD4 were to be conducted every 6 months;
and ALT and creatinine were to be conducted every 12 months.
CD4 testing was not widely available between 2007 and 2009 as it
was mostly available in district hospitals or higher level facilities
and at selected primary healthcare facilities which were initiating
ART. In 2007 there were 46 CD4 machines and by 2009, 59
facilities in 47 out of the 62 districts countrywide had CD4
machines [22]. CD4 count testing was therefore done at each
ART initiating sites if available, as there were no collection and
transportation of blood samples to facilities with CD4 count
machines. Patient demographic, clinical and laboratory informa-
tion and visit dates are recorded in MOHCC medical records
maintained at the health facility.
Treatment Outcome Measures
During data collection, the most recently documented status of
each patient at the last clinic visit date was abstracted and
recorded as alive-continued ART, transferred out, stopped, died,
lost to follow-up (LFU), defaulted, and other. For this assessment,
‘‘retention’’ referred to a patient who was alive and known to be
receiving ART at the same clinic where they initiated ART and
‘‘attrition’’ referred to a patient who was documented as having
died, stopped ART, defaulted or was lost to follow-up. A patient
defined as ‘‘defaulted’’ had been absent from a healthcare facility
for#90 days whilst one who was ‘‘lost to follow-up’’ was absent for
.90 days after his/her last scheduled appointment with the health
care provider or pharmacy. The date of LFU was recorded as the
date of the most recent visit or one day after ART initiation if
patients only attended the initiation visit. Patient retention was
calculated as the difference between date of ART initiation and
the latest clinic visit date. Patients who were documented to have
transferred out of a clinic before the time point of interest (either 6,
12, 24 or 36 months of follow-up) were excluded from the
numerator and denominator of the relevant retention/attrition
proportion.
For time-to-event analyses, patients who transferred to another
clinic were censored at the date of transfer. However, for
estimating retention proportions at 6, 12, 24, and 48 months,
transfers were excluded from the retention analysis. Baseline CD4
was defined as the value on the date closest to ART start date but
not more than 182 days prior to that date or more than 1 day after
that date. Values for clinical stages, weights and CD4 counts at 6,
12 and 24 months of follow-up, were taken as values obtained on
the dates closest to 182, 365 and 730 days, respectively.
Treatment failure was defined using clinical or immunological
criteria. Viral load testing was not widely implemented due to the
associated prohibitive costs. A patient on ART for at least 6
months presenting with new or recurrent WHO stage 4 condition
(clinical failure) or a fall to CD4 count/percentage or persistent
CD4 level below 100 cells (immunological failure) were considered
treatment failure. The preferred 2nd line ART for adults that failed
1st line ART was Tenofovir, Lamivudine, and Lopinavir/
Ritonavir.
Statistical Analysis
All analyses were performed using SAS 9.2 (SAS Institute Inc.,
Cary, NC) and Stata/IC 10.1 (StataCorp, 2009, Stata Statistical
Software: Release 10.1, College Station, TX). Statistical analyses
were weighted to account for unequal probabilities of selection and
accounted for the complex design of the survey (i.e. stratification
and clustering).
Missing data were assumed missing at random (MAR) [23] and
were multiple imputed via chained equations using the ice [24–26]
procedure in Stata. Twenty imputed datasets were created and
estimates were combined according to Rubin’s rules [23] using the
mim procedure [27]. The imputation model included the Nelson-
Aelen estimate of cumulative hazard [28], baseline demographic
and clinical variables, and the event indicator. Time-to-event data
were complete for all individuals. Twenty-five patients were lost to
follow-up after their first clinic visit and were assigned one day of
person-time.
Stratified Kaplan-Meier curves were used to graphically assess
retention proportions. These analyses were limited to the first
imputed dataset. Cox proportional hazards models were used to
identify factors (e.g., year of ART initiation, gender, baseline CD4
count, baseline WHO stage, baseline body weight, active TB
treatment, baseline haemoglobin) associated with attrition based
on prior research. Hazard ratios (HRs), adjusted hazard ratios
(AHRs) and their respective 95% confidence intervals (CI) and p-
values were calculated. In multivariate-analysis HRs were adjusted
for the potential confounding effects of sex, marital status, rural/
urban location of health facility, baseline CD4 count, baseline
WHO staging, baseline weight, prescribed CTX, level of health
care and site size of ART clinic. The proportional hazards
assumption was assessed via a variety of methods including log-log
plots and Kaplan-Meier versus Cox predicted plots and results of
these analyses suggested that the proportional hazards assumption
appeared to be reasonable.
Results
Demographic and clinical characteristics of ART patients
and characteristics of ART sites including clinical
practices
A total of 3,919 medical charts of eligible ART patients were
located and abstracted. Data were missing at baseline for 630
(16%) patients for WHO clinical stage, 2,085 (53%) for CD4 T-
cell count, 1,049 (26.8%) for body weight, 3,021 (77%) patients for
haemoglobin and 825 (21%) for cotrimoxazole prescription.
Table 1 describes analysis results for both the original and
imputed datasets; in the following text, weighted imputed data are
reported.
At enrolment into OI/ART, patient median age was 37 years,
and 64% were female of whom 5.8% were pregnant. Fifty-two
percent of the patients were married or cohabitating and 25.5%
were widowed. Fifty-three percent of patients initiated treatment
at an urban clinic and 46.7% initiated treatment at a rural clinic.
Almost three quarters (72.6%) of patients initiated ART at a
district or mission hospital; 16.8% initiated ART at a central or
provincial hospital; and 10.6% initiated treatment at a primary
healthcare facility.
Median CD4+ cell count at baseline was 121 cells/mL. Median
CD4 cell count at baseline was slightly lower in males (104 cells/
mL) than in females (127 cells/mL). At baseline, 22.4% of patients
had a CD4 cell count less than 50 cells/mL, and 53.4% had a cell
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count between 50 and 200. A higher proportion of males had a
CD4+ cell count below 50 cells/mL than females.
In terms of WHO clinical staging, 70.5% were diagnosed with
stage III disease, 15.1% were diagnosed with stage IV disease, and
the remaining were diagnosed with stages II and I disease. A
slightly higher proportion of males were diagnosed with stage IV
disease compared to females (males – 16.4% and females- 12.8%).
At baseline, 13.3% of patients weighed less than 45 kilograms
(kgs) and 60% weighed between 45 and 60 kgs. The median
weight of females was 53.2 kgs and of males was 57 kgs.
Treatment for tuberculosis at the time of enrolment into an OI
clinic was documented for 12% of the 2,231 patients with
information about TB treatment at OI clinic enrolment. A higher
proportion of male ART patients were on TB treatment at OI
clinic enrolment than female ART patients.
Table 1. Demographic and clinical characteristics of patients at ART initiation and characteristics of ART sites, including clinical
practices.
All Multiple Imputation (N=3,919)
N N
Percentage (95% CI) Or Median
(IQR)
Percentage (95% CI) Or Median
(IQR)
Sex
Female 2,514 3,907 64.1% (62.2–65.9) 64.0% (62.2–65.9)
Male 1,393 3,907 35.9% (34.1–37.8) 36.0% (34.1–37.8)
Missing 12 3,919 0.3% –
Age At ART Start (Years)
All 3,733 3,733 37 (32–45) 37 (32–45)
Missing 186 3,919 0.0% –
Female 2,388 2,388 36 (31–44) 36 (31–44)
Male 1,335 1,335 39 (34–48) 39 (34–48)
Marital Status
Single/Divorced 651 3,003 21.8% (18.1–25.4) 22.0% (19.0–25.2)
Married/Cohabiting 1,577 3,003 52.5% (49.8–55.2) 52.4% (50.1–54.7)
Widowed 775 3,003 25.7% (22.1–29.4) 25.5% (22.5–28.5)
Missing 916 3,919 23.4% –
WHO Stage
I/Ii 390 3,289 12.4% (6.8–18.1) 14.4% (8.6–20.1)
Iii 2,413 3,289 73.5% (66.9–80.1) 70.5% (63.9–77.1)
Iv 486 3,289 14.1% (9.7–18.4) 15.1% (11.4–19.0)
Missing 630 3,919 16.1% –
CD4 T-Cell Count (Cells/Ml)
$200 712 1,834 22.7% (19.5–25.9) 24.1% (19.6–28.6)
50–,200 2,206 1,834 54.9% (51.2–58.7) 53.4% (49.8–57.1)
,50 1,875 1,834 22.4% (20.2–24.6) 22.4% (19.8–25.1)
Missing 2,085 3,919 53.2% –
Weight
.60 Kg 779 2,870 26.5% (22.9–30.1) 26.8% (23.5–30.0)
45–60 Kg 1,722 2,870 60.4% (57.9–62.3) 60.0% (57.6–62.3)
,45 Kg 369 2,870 13.1% (10.3–16.0) 13.3% (10.8–15.8)
Missing 1,049 3,919 26.8% –
Prescribed CTX
Yes 2,985 3,094 96.7% (95.0–98.3) 96.6% (95.2–98.1)
No 109 3,094 3.3% (1.7–5.0) 3.4% (1.9–4.8)
Missing 825 3,919 21.1%
Site Type
Rural 1,975 3,919 46.7% (22.0–71.3) 46.7% (22.0–71.4)
Urban 1,944 3,919 53.3% (28.7–78.0) 53.3% (28.6–78.0)
Missing 0 3,919 0.0% –
doi:10.1371/journal.pone.0086305.t001
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The majority of ART patients (96.6%) were prescribed CTX at
baseline and 100% of the 3,759 patients with documented data
were prescribed a first-line regimen. Three percent of patients had
documented drug substitutions for active TB, toxicity, pregnancy
and other reasons. Only six (0.2%) of patients had documented
treatment failure and were switched to second-line antiretroviral
treatment. Fifteen patients were documented to have stopped
ART because of drug toxicity, pregnancy and other reasons.
Patient outcomes
Of 3,919 patients who initiated ART, 90.7%, 78.1%, 68.8%
and 64.4% remained alive on ART at their initiating site after 6,
12, 24 and 36 months, respectively (Table 2). Retention on ART
appeared higher in females when compared to males at 24 months
(71.1% vs 64.6%) and at 36 months (66.9% vs. 59.7%).
Median follow-up duration was 1.36 years. By 6 months, 4.1%
had died and 4.9% had been LFU; by 12 months, 4.8% had died
and 16.1% had been LFU; by 24 months, 6.7% had died and
23.5% had been LFU; and by 36 months 8.5% had died and
25.2% were LFU. Of patients who died, 59.8% died within 90
days of starting ART. Of patients who were LFU, 15.6% were lost
within 90 days and 68% were lost within 365 days of starting
ART.
Clinical improvement was seen among both male and
female patients. Increases in body weight and in CD4 cell counts
were observed between baseline and follow-up appointments at 6,
12, and 24 months among patients with weight and/or CD4 cell
count data. Table 3 describes weight gains in ART patients.
Increases in CD4+ cells were also observed after ART initiation
among the few patients with CD4+ count measurements
(Table 4). For female patients, median CD4+ count gains from
baseline were 122, 171, and 265 cells/mL at 6, 12, and 24 months,
respectively. For male patients, median CD4+ count gains from
baseline were 125, 130, and 179 cells/mL at 6, 12, and 24 months,
respectively.
Factors associated with attrition
Table 5 shows the results of univariate and multivariable
analyses of factors associated with attrition.
Male sex was associated with an increased risk of attrition (AHR
1.24; p=0.004). Baseline WHO stage IV was associated with an
increased risk of attrition (AHR 1.73; p = 0.012) as compared with
WHO stages I/II. A baseline CD4 cell count,50 (HR 1.36,
p=0.05) was associated with higher attrition as compared with
CD4 cell count .200 in univariate analysis, however, no
associations between CD4 cell count and attrition were observed
in the final multivariable survival model. Patients with baseline
weights of 45–60 kilograms (AHR 1.25; p=0.02) and ,45
kilograms (AHR 2.03; p= .000) at baseline had an increased risk
of attrition as compared with those patients with weights .60
kilograms (Figure 1).
While the majority of patients were prescribed cotrimoxazole
prophylaxis at baseline, those who did not receive a cotrimoxazole
prescription had significantly increased risk of attrition (AHR 1.94;
p= .007).
Initiating ART at an urban site, as compared with a rural site,
was marginally associated with attrition (AHR 2.13; p=0.06).
Initiating ART at a central/provincial hospital (AHR 3.21;
p=0.06) or at a district/mission hospital (AHR 3.49; p=0.04) as
compared with a primary healthcare clinic, was marginally
associated with a higher risk of attrition (Figure 2).
Discussion
Clinical outcomes and retention in care were similar to findings
in other Sub-Saharan African countries despite severe challenges
to the health system, hence demonstrating that rapid ART scale-
up with good clinical outcomes is feasible even under difficult
circumstances. Retention rates in Zimbabwe are very similar to
those estimated by Fox and Rosen [4] in a recent meta-analysis of
published cohort data from 16 countries in sub-Saharan Africa in
which estimated retention rates of ART patients at 6, 12, 24 and
36 months, were 86.1%, 80.2%, 70.0% and 64.6% respectively.
Whilst our findings may have been similar to those in other Sub-
Saharan African countries, we hypothesized that they would be
worse. This is in view of existing hyperinflation in Zimbabwe
during the period under review whereby cumulative inflation
between 1997 and 2007 was 3.8 billion percent whilst the official
inflation figure for February 2008 was 165,000 percent [29]. This
hyperinflation was associated with increasing emigration of
doctors and shortages of essential medical supplies in health
facilities [14]. Despite this situation we managed to have
comparatively similar findings through funding from bilateral aid
and international multilateral institutions such as Global Fund to
fight AIDS,
Tuberculosis and Malaria (GFTATM) and the Expanded
Support Programme for HIV and AIDS (ESP) which ensured
antiretroviral medicines were procured and distributed country-
wide among other interventions. There was also support from ESP
towards the human resource retention scheme [30] which
supported primary counsellors who offered treatment adherence
counselling and psychosocial support to patient whilst a significant
amount was channelled towards retention of critical staff such as
doctors who were responsible for initiating patients on ART,
managing co-morbidities and complications as well as mentoring
nurses in providing follow-up care. In 2009 alone, international
sources contributed over 75% of total HIV spending [18] since
internal funding sources such as the National AIDS levy were
insignificant due to the eroded value of the Zimbabwe dollar.
Table 2. Retention of patients after 6, 12, 24, and 36 months.
Total Females Males
N Percentage (95%CI) N Percentage (95%CI) N Percentage (95%CI)
6 months 3,739 90.7 (86.1–93.8) 2,413 91.9 (87.3–94.9) 1,316 88.5 (83.4–92.2)
12 months 3,641 78.1 (69.7–84.7) 2,352 79.6 (71.1–86.2) 1,280 75.3 (66.6–82.3)
24 months 2,003 68.8 (58.5–77.5) 1,286 71.1 (60.3–80.0) 711 64.6 (54.1–73.8)
36 months 806 64.4 (55.7–72.3) 522 66.9 (56.6–75.8) 282 59.7 (51.1–67.8)
Note: These analyses are not based on imputed data.
doi:10.1371/journal.pone.0086305.t002
Outcomes of Antiretroviral Therapy in Zimbabwe
PLOS ONE | www.plosone.org 5 January 2014 | Volume 9 | Issue 1 | e86305
The median CD4 cell count at ART initiation was low although
this was slightly higher than that reported in a systematic review of
39 patient cohorts in Sub-Saharan Africa [4]. We also note that
nearly half of the cohort initiated ART at very low CD4 counts
(50–200 cells). Whilst ART was recommended in all patients
eligible for ART according to 2006 WHO guidelines [31] such
patients with very low CD4 counts were prioritized and fast
tracked for ART over those with higher CD4 counts as these
usually have higher risk of dying. Slightly over half of the cohort
did not have documentation of a baseline CD4 count test. Further
analysis shows that these patients without CD4 counts did not
constitute any specific sub-group of patients. Scale up of point-of-
care CD4 count machines could greatly improve linkage to ART
care and patient retention as they have been shown locally to be
more suitable for immediate decision making, improve testing
access in both rural and urban settings and can also be used by
nurses when compared to conventional laboratory CD4 machines
[32].
For those ART patients in Zimbabwe with documented follow-
up data, there were some signs of immunologic and clinical
improvement. Median gains in CD4+ cell counts at 6, 12, 24 and
36 months were similar to those reported from Rwanda [33],
Mozambique [34] and Cote d’Ivoire [35] and other low- and
high-income settings [36]. These immunologic gains in the
absence of virological monitoring maybe highly associated with
viral load suppression although it has recently been shown that
immunologic monitoring coupled with monitoring viral load and
duration on ART is very useful in assessing risk of patient
mortality [37]. In our study the treatment failure rate which was
based on a clinical/immunologic definition was lower than the
average treatment failure rate of 2.64% reported for Africa in a
systematic review by Renaud-Thiery F et al [38] when similarly
based on the clinical/immunologic criteria. However, the clinical/
immunologic criteria for treatment failure is known to be less
sensitive in comparison to virological monitoring [39] and
treatment failure rates were found to be approximately three
times higher when viral load was used to define failure in the
systematic review by Renaud-Thiery et al [38]. In Zimbabwe,
findings from routine cohort monitoring at 12 sentinel sites for
HIV drug resistance conducted between 2009 and 2011 show that
10.4% of 958 HIV-infected patients had viral load .1000 copies/
ml at 12 months after starting ART, and upon excluding those
with baseline gene mutations the proportion that had acquired
HIV drug resistance was 8.9% [40]. This highlights a need for
integration of viral load monitoring into routine ART care.
Median gains in weight were also noted in this study and such
observations during antiretroviral therapy have been associated
with better patient outcomes [41]. Similar to our setting, the same
has been reported in Rwanda [33] and Mozambique [34].
Routine recording of weight was notably a poor practice both at
ART initiation and in follow up visits in this study and needs to be
scaled up since WHO recommends monitoring weight [42] as a
useful indicator of a patient’s response to ART.
As found in other sub-Saharan African countries, retention of
patients initiating ART at primary healthcare facilities in
Zimbabwe was better than for those initiating ART at higher
levels of care, in particular district/mission hospitals [10,11,43,44].
In further analysis we noted that there were more LFTUs in
district/mission hospitals compared to primary care facilities.
Whilst these LFTUs could have been silent deaths they could as
well be patients who unofficially transferred from centralised
services to PHCs where they can access better quality medical
attention as found in a systematic review of mostly Sub-Saharan
African studies [45]. During the study period under review, ART
initiations were mostly led by doctors who were mostly situated in
higher level health facilities due to their shortage. It is therefore
likely that patients would travel from rural settings to district or
mission hospitals, for ART initiations and there after unofficially
transfer to other less congested peripheral facilities for follow-up
care. This in part may overestimate attrition levels in these higher
level facilities. To limit such potential biases, transfers-in were not
sampled during data collection whilst official transfers-out where
eliminated from the analysis.
This further suggests the importance of continuing the
decentralization of OI/ART services through the accreditation
of peripheral health facilities and outreach sites so that they can
conduct ART initiations as described in the 2011 Zimbabwe
Guidelines for the Decentralization of OI/ART Services [46].
This should also be coupled with endorsing nurse-led ART
initiation, given the high shortage of medical doctors. In our view
decentralisation improved patient retention in the National ART
Programme, particularly at primary care facilities by decongesting
ART initiations at higher level facilities although this may
inevitably have contributed to high losses-to-care of patients from
centralised facilities with high patient volumes who unofficially
transferred to primary health facilities were they could access
better quality of medical care and follow-up. To address future
attrition we propose adoption of patient adherence groups for
Table 3. Median weight gains (kilograms) during ART stratified by gender.
6-month gains 12-month gains 24-month gains 36-month gains
Median (IQR) N Median (IQR) N Median (IQR) N Median (IQR) N
All 3.0 (20.8–7.0) 1,621 4.5 (0.0–9.0) 1,444 5.0 (1.0–10.0) 665 6.0 (0.0–11.0) 209
Female 3.0 (21.0–7.0) 1,058 5.0 (0.0–10.0) 955 5.0 (1.0–12.0) 429 6.0 (0.0–11.0) 134
Male 3.0 (0.0–6.8) 560 4.0 (0.0–8.0) 486 5.0 (1.0–9.8) 234 4.0 (0.5–9.0) 73
Note: These analyses are not based on imputed data.
doi:10.1371/journal.pone.0086305.t003
Table 4. Median CD4 T-cell count (cells/mL) gains during ART
stratified by gender.
6-month gains 12-month gains 24-month gains
Median (IQR) N Median (IQR) N Median (IQR) N
All 122 (65–189) 222 157 (85–240) 279 252 (162–353) 162
Female 122 (68–193) 139 171 (89–252) 183 265 (180–367) 106
Male 125 (63–172) 83 130 (80–211) 96 179 (113–298) 56
Note: These analyses are not based on imputed data.
doi:10.1371/journal.pone.0086305.t004
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stable ART patients. In an urban setting in South Africa, these
adherence groups have resulted in a 57% reduction in loss-to-care
compared to those attending routine nurse-led care [47] whilst in
rural Mozambique they have resulted in a remarkable 1-year
patient retention of 97% [44].
As reported by other ART Programmes in sub-Saharan Africa,
male sex and advanced disease at ART initiation were associated
with patient death or loss to follow-up [33–35,48–50]. In our
study, proportionally more women (64%) than men (36%) were on
ART as reported by other Southern African countries [51]. This
corresponds with national HIV testing patterns in Zimbabwe in
which fewer women (42%) than men (62%) report never having
been tested for HIV [13] and also with the observation that male
HIV patients in sub-Saharan Africa are more likely than females
to have advanced HIV disease at ART initiation and to be at
increased risk of LTFU and/or death [49,52,53].
In many African settings, women have better access than men to
HIV testing and treatment services through integration of routine
‘‘opt-out’’ provider-initiated testing and counselling in antenatal
care settings [54] as an entry point into prevention-of-mother-to-
child HIV transmission (PMTCT) services, even though attrition
rates between testing HIV-positive in pregnancy and accessing
ART continue to be unacceptably high [55,56]. A recent study by
Takarinda and colleagues [57] suggests that even when men do
have access to HIV testing and counselling they decline it. HIV
testing rates can be scaled up through innovative strategies such as
roll-out of routine opt-out mobile, home-based or work-place
voluntary testing and counselling [58–60] which may improve
male participation in order to achieve earlier HIV diagnosis and
also provider initiated testing and counselling in a healthcare
setting can improve testing for both genders. Strategies aimed at
improving linkage to care from HIV testing may also help achieve
earlier treatment and resultantly improve patient treatment
outcomes.
A large percentage of the cohort had low body weight at
baseline and consistent with other ART Programmes [33,34,49]
the probability of retention was lower in patients with low body
weight at ART initiation. Although it is not known whether
undernourishment is causally related to poor ART outcomes or is
merely associated [61], hunger is a frequently reported barrier to
adherence and the side effects and toxicity of some ARVs can be
potentiated if taken without food [62]. Adoption of food
supplementation as a strategy aimed at increasing patient retention
would be useful in our setting. This strategy has been shown to
Table 5. Factors associated with attrition including patient characteristics at ART initiation, clinical practices and healthcare facility
type and location.
Attrition





100PY HR (95% CI) p-value AHR (95% CI) p-value
Sex
Female 2,514 19.3 19.3 1.0 1.0 –
Male 1,393 24.0 24.0 1.22 (1.07–1.39) 0.003 1.24 (1.08–1.43) 0.004
CD4 T-cell count (cell/mL)
.200 402 14.8 19.4 1.0 – 1.0 –
.50–#200 1,031 13.2 19.5 1.03 (0.76–1.39) 0.861 0.97 (0.74–1.26) 0.806
,50 401 22.7 25.8 1.36 (1.01–1.85) 0.045 1.22 (0.89–1.67) 0.189
WHO Stage
Stage I/II 390 15.8 17.5 1.0 – 1.0 –
Stage III 2,413 19.1 19.9 1.16 (0.76–1.77) 0.481 1.15 (0.74–1.78) 0.531
Stage IV 486 26.6 30.3 1.73 (1.19–2.50) 0.006 1.73 (1.14–2.61) 0.012
Weight
.60 kgs 779 15.2 16.3 1.0 – 1.0 –
45–60 kgs 1,722 19.0 20.4 1.25 (1.03–1.51) 0.024 1.25 (1.04–1.51) 0.020
,45 kgs 369 33.4 34.7 2.07 (1.53–2.79) 0.000 2.03 (1.43–2.87) 0.000
Prescribed CTX
Yes 2,985 16.7 20.3 1.0 – 1.0 –
No 109 34.5 39.5 1.82 (1.22–2.72) 0.005 1.94 (1.21–3.09) 0.007
Level of Healthcare
Primary healthcare facility 415 8.4 8.4 1.0 – 1.0 –
District/Mission hospital 2,844 20.1 20.1 2.24 (0.81–6.20) 0.116 3.49 (1.09–11.20) 0.036
Central/Provincial hospital 660 29.8 29.8 3.16 (1.15–8.72) 0.027 3.21 (0.96–10.75) 0.058
Site Type
Rural 1,975 14.8 14.8 1.0 – 1.0 –
Urban 1,944 27.8 27.8 1.75 (0.99–3.09) 0.054 2.13 (0.95–4.77) 0.064
doi:10.1371/journal.pone.0086305.t005
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improve adherence to ART among food-insecure adults in
Zambia [63] and also is associated with reduced morbidity and
hospitalisations [64].
Anaemia has been shown to be an independent indicator of
mortality and of disease progression among HIV-infected persons
in sub-Saharan Africa [48,49,65,66]. Unfortunately, levels of
anaemia could not be determined in our study because only 20.2%
of patients had a documented haemoglobin level at baseline and
even fewer had documented haemoglobin levels at follow-up visits.
Zimbabwe has begun gearing up routine clinical laboratory testing
for HIV-infected patients which should improve the capacity of
clinicians to screen for anaemia.
Attrition was closely associated with advanced disease status at
ART initiation as reported by ART programmes throughout sub-
Figure 1. Retention stratified by weight at baseline.
doi:10.1371/journal.pone.0086305.g001
Figure 2. Retention stratified by level of healthcare.
doi:10.1371/journal.pone.0086305.g002
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Saharan Africa [45,67]. Clinical predictors of attrition in
Zimbabwe at initiation of ART included WHO clinical stage III
and low body weight (,45 kg). Whilst those in WHO stage IV
were at increased risk of attrition compared to those in WHO
stage I/II, they constituted a small proportion of the cohort. The
majority where in WHO stage III at ART initiation and although
they were not significantly at higher risk of attrition, these patients
had advanced HIV disease and where therefore also at increased
risk of having poor outcomes compared to those in stage I/II.
Data from South Africa and other countries demonstrate that
starting ART earlier (at CD4,350 cells/mL) results in improved
treatment outcomes [68]. Similar to other programmes
[34,45,48,49], a large proportion of reported mortality in our
study population occurred within 6 months of initiating ART.
During the period of our study, adults infected with HIV were
eligible for ART if they presented with WHO clinical stage IV
and/or CD4+ ,200 cells/mL. It is well known from literature that
initiation of ART with poor health at baseline (specifically CD4
counts,200cells/ml or WHO stage IV or V) can lead to immune
reconstitution inflammatory syndrome which can occur within
days to months from ART initiation and has clinical effects
ranging from a mild, self-limiting illness to severe morbidity and
mortality. [69,70] Our findings underscore the importance of
initiating treatment at an earlier disease stage as recommended by
the recently published 2013 WHO Consolidated HIV Guidelines
[71].
The 2013 Consolidated HIV Guidelines present opportunities
for Zimbabwe to provide early HIV treatment and care services
for HIV infected people using a higher CD4 threshold of,500. In
2013 alone, the number of people in need of treatment will
increase by 25% from 685,360 (based on the 2010 guidelines) to
857,842 [12]. It is likely that the country will adopt Tenofovir
+Lamivudine+Efavirenz, as the preferred 1st line ART regimen for
adults and adolescents. Although more costly than stavudine-based
regimens; it is hoped that as more countries adopt the guidelines
and order large volumes of medicines, the drug price for tenofovir-
based regimens will decline over time with economies of scale. It is
feasible though that Zimbabwe will successfully adopt and
implement the 2013 WHO HIV guidelines using the recently
approved Global Fund HIV grant of USD 555 million.
Despite our study having a large sample which enables us to
confidently infer our findings to the entire national ART
programme, there were limitations to our study. These limitations
were mainly related to data abstraction of routinely collected
programme data hence this accounted for missing data in a
number of variables collected. We were also unable to establish
true patient outcomes for those patients that were classified as
LFTU or defaulters. Also the exclusion of patients that transferred
out or transferred into the selected ART sites may limit inference
of our findings to this patient group although further comparison
of the abstracted ‘‘transfer-out’’ patient group to the rest of the
cohort showed no differences in baseline characteristics. The
above mentioned limitations may therefore lead to biased
estimates on patient retention and attrition-associated factors in
the national patient cohort.
Conclusion
The assessment covered a difficult period for Zimbabwe and
despite this, the rapid scale-up of ART has been remarkable. Also
whilst retention and clinical outcomes are comparable or better
than those reported from programmes in other sub-Saharan
African countries, there is still need to monitor and improve on
retention, and some strategies may include the adoption of ART
adherence clubs [43] and issuing out of mobile phone short
message services as drug pick-up and clinic visit reminders to
patients [72] as shown in other settings. Adoption of food
supplementation can be another feasible strategy to improve
patient retention among food insecure adults.
In addition, our findings indicate that increased efforts are
needed to ensure that persons with HIV seek care and initiate
treatment before they have advanced disease and to expand access
of services through decentralisation and targeted services (e.g., for
men).
HIV testing rates and linkages to care, especially for men, need
to be improved (perhaps through the provision of services in non-
traditional venues) in order to achieve earlier diagnosis and
treatment whilst CD4 cell count testing needs to be scaled up at
district level to assess ART eligibility [55,66] and this can be
through the use of CD4 point-of-care machines.
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